List view / Grid view
What can we learn from tumours after they stop responding to treatment? By studying patient tissue directly, researchers are finding new ADC targets that conventional screening often misses.
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
17 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The extension agreement will trigger a €1 million payment to Ablynx, and MSD will extend their funding of the research collaboration to September 2018...
25 November 2015 | By
Ablynx and Novo Nordisk hope to discover and develop novel multi-specific drug candidates using Ablynx's proprietary Nanobody technology...
15 October 2015 | By Victoria White
The nanobody construct binds to two different immune modulators, proteins believed to be targets for the development of important cancer immunotherapies...
22 July 2015 | By Victoria White
Ablynx has expanded its immuno-oncology collaboration with MSD to address an increased number of immune checkpoint modulator targets...
18 May 2015 | By Victoria White
Ablynx is set to collaborate with Genzyme to investigate Nanobodies against a target that plays an important role in multiple sclerosis (MS)...
